| Literature DB >> 31210903 |
Alireza Aghaz1, Alireza Alidad2, Ehsan Hemmati3, Hussein Jadidi4, Leila Ghelichi2,5.
Abstract
Background: Dysphagia is the most prevalent sign of multiple sclerosis (MS) which can reduce the quality of life and augment mortality in the final stages of MS. We presented a systematic review to estimate the prevalence of dysphagia in general and separately for each evaluation method (subjective and objective), and to analyze the causes of this rampant disease.Entities:
Keywords: Dysphagia; Multiple Sclerosis; Prevalence; Systematic Review
Year: 2018 PMID: 31210903 PMCID: PMC6555886
Source DB: PubMed Journal: Iran J Neurol ISSN: 2008-384X
Figure 1The flowchart of study selection process
Prevalence of dysphagia in multiple sclerosis (MS) via subjective screening method
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| Shibasaki, et al.[ | UK | Cross- | 264 | 40.5 | Coding sheet contained | - | 10.3 | - | 23.1 |
| Hartelius and | Sweden | Cross- | 203 | < 55.0 | 22 questionnaire tools | - | > 10 (70%) | - | 33.0 |
| Abraham, et al.[ | USA | Cross- | 525 | 45.0 | One-page dysphagia- | - | - | 5.2 | 43.0 |
| Thomas and Wiles [ | UK | Cross- | 79 | 44.0 | A 26-part questionnaire, | - | 11.8 | 6.0 | 43.0 |
| De pauw, et al.[ | Belgium | Cross- | 308 | 50.0 | Johns Hopkins swallowing | RRMS: (32), | 17.0 | 6.5 | 29.0 |
| Bergamaschi, et al.[ | Italy | Cross- | 226 | 40.5 | DYMUS questionnaire | - | 10.1 | 3.1 | 35.0 |
| Poorjavad, et al.[ | Iran | Cross- | 101 | 34.0 | NDPCS | RRMS: (74.3), | 5.9 | 2.2 | 31.7 |
| Lasemi, et al.[ | Iran | Cross- | 400 | 34.2 | EDSS | PPMS: (30.8), | < 7 (61.5%) | - | 21.0 |
| Levinthal, et al.[ | USA | Cross- | 218 | 47.6 | MDADI questionnaire | RRMS: (70.6), | 13.3 | - | 21.1 |
| Solaro, et al.[ | Italy | Cross- | 1875 | 43.3 | DYMUS questionnaire | RRMS: (69.0), | 11.4 | 3.3 | 31.3 |
| Sales, et al.[ | Brazil | Cross- | 100 | 45.5 | DYMUS questionnaire | RRMS: (66.0), | 8.0 | 3.0 | 58.0 |
| Alfonsi, et al.[ | Italy | Prospective | 26 | 44.2 | DYMUS questionnaire | RRMS: (34.6), | - | 4.7 | 76.9 |
| Danesh-Sani, et al.[ | Iran | Cross- | 500 | 44.6 | A standard neurological | - | 0-7 (63.2%) | - | 26.6 |
| Chauvet, et al.[ | France | Cross- | 150 | - | DYMUS questionnaire | - | - | - | 44.0 |
| Goncalves, et al.[ | Brazil | Cross- | 34 | 38.0 | NOT-S | - | - | - | 55.8 |
| Pajouh, et al.[ | Iran | Cross- | 105 | 33.8 | DYMUS questionnaire | - | 3.5 ± 3.1 (mean ± | 1.8 ± 1.3 (mean ± | 52.4 |
RRMS: Relapsing remitting multiple sclerosis; PPMS: Primary progressive multiple sclerosis; SPMS: Secondary progressive multiple sclerosis; EDSS: Expanded disability status scale; NDPCS: Northwestern dysphagia patient check sheet; MDADI: MD Anderson dysphagia inventory; DYMUS: Dysphagia in multiple sclerosis; NOT-S: Nordic orofacial test-screening; SD: Standard deviation
Prevalence of dysphagia in multiple sclerosis (MS) via objective screening method
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| Wiesner, et al.[ | Switzerland | Cross-sectional | 18 | 47.0 | Clinical and VFSS | - | - | 6.2 | 55.6 |
| Calcagno, et al.[ | Italy | Cross-sectional | 143 | 49.9 | Direct examination | - | 17.03 | 6.8 | 34.3 |
| Terre-Boliart, et al.[ | Spanish | Cross-sectional | 23 | - | Clinical and VFSS | - | - | 7.4 | 83.0 |
| Fernandes, et al.[ | Brazil | Cross-sectional | 120 | 38.5 | Clinical and VFSS | RRMS: (65.8), | - | 5.0 | 90.0 |
| Alfonsi, et al.[ | Italy | Prospective | 26 | 42.2 | FEES | RRMS: (34.6), | - | 4.7 | 53.8 |
| Beckmann, et al.[ | Turkey | Prospective | 51 | 32.2 | EMG | RRMS: (100), | 4.52 | - | 35.0 |
VFSS: Videofluoroscopic swallowing study; FEES: Fiberoptic endoscopic evaluation of swallowing; EMG: Electromyography; RRMS: Relapsing remitting multiple sclerosis; PPMS: Primary progressive multiple sclerosis; SPMS: Secondary progressive multiple sclerosis; EDSS: Expanded disability status scale
Figure 2Rate of dysphagia prevalence in multiple sclerosis (MS)-affected patients and its 95% confidence interval (CI) in the considered studies based on the random effects model; the midpoint of each line shows the estimation of the prevalence and the length of the line indicates the 95% CI of each study. The rhombic sign shows the rate for the prevalence combination in the studies.
Correlation between the prevalence of dysphagia and the severity of the disease, the duration of the disease, and the stages of multiple sclerosis (MS)
|
|
|
|
| |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Prevalence of | Correlation coefficient | 0.11 | -0.52 | -0.26 | 0.26 | 0.18 |
| P | 0.7200 | 0.1800 | 0.5200 | 0.5200 | 0.6300 | |
| N | 14 | 10 | 10 | 10 | 10 | |
EDSS: Expanded disability status scale; RRMS: Relapsing remitting multiple sclerosis; PPMS: Primary progressive multiple sclerosis; SPMS: Secondary progressive multiple sclerosis
The significance level in this study is 0.5000.
Figure 3Meta-regression graph of dysphagia prevalence in the patients affected to multiple sclerosis (MS) according to the considered duration of the studies; the circles show the weight of the studies.
Figure 4Meta-regression graph of dysphagia prevalence in the patients affected to multiple sclerosis (MS) according to the sample size; the circles show the weight of the studies.
Figure 5Meta-regression graph of dysphagia prevalence in the patients affected to multiple sclerosis (MS) according to the average age of the patients; the circles show the weight of the studies.
Figure 6Funnel plot for the included studies with regards to the “subjective” group
Figure 7Funnel plot for the included studies with regards to the “objective” group
Figure 8Geographical dispersion of the studies about dysphagia prevalence in multiple sclerosis (MS)-affected patients